Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44) | RFA ES 17 007

Opportunity Information: Apply for RFA ES 17 007

The grant opportunity titled "Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44)" is a National Institutes of Health (NIH) Small Business Innovative Research (SBIR) solicitation focused on advancing laboratory tools that can more efficiently and accurately evaluate how chemicals disrupt cell differentiation. In practical terms, NIH is looking for small businesses to create new assay platforms, ideally at medium- to high-throughput scale, that can expose pluripotent stem cells or induced pluripotent stem cells (iPSCs) to potential toxicants and then measure how those exposures alter the differentiation process and the characteristics of the resulting specialized cell types. The central scientific aim is to move beyond simple measures of cell death or stress and instead capture developmental and lineage-specific effects, which can be critical for understanding toxicity that emerges during development or tissue formation.

A key emphasis of the FOA is assay development that can interrogate mechanisms of chemically induced biological activity. That means applicants are expected to design approaches that do more than provide a yes/no toxicity flag. The assays should be capable of generating informative readouts tied to differentiation pathways and cellular identity, such as shifts in lineage markers, altered timing of differentiation, changes in cell population composition, or functional deficits in the differentiated cells. Because this is framed as a screening and prioritization tool, the intent is that the resulting methods can help rank or triage large numbers of environmental or industrial chemicals for more detailed follow-up toxicology studies, rather than relying solely on slower, resource-intensive animal tests or low-content in vitro endpoints.

The opportunity also highlights the value of incorporating genetic diversity into these assay systems. In toxicology, genetic variation can strongly influence susceptibility and response, and iPSC-based platforms make it increasingly feasible to test chemical effects across different genetic backgrounds. NIH signals that assays able to include multiple donor lines, panels representing diverse populations, or other strategies that account for variability would be especially useful. The broader rationale is that this could improve the predictive power of in vitro findings for real-world human responses and provide insight into why certain individuals or groups may be more sensitive to particular toxicants.

From a programmatic standpoint, the assays developed under this FOA are expected to support more predictive models of in vivo biological response. The agency is essentially encouraging the development of testing systems that better approximate human biology and developmental processes, which can strengthen hazard identification, refine risk assessment, and improve decision-making about chemical safety. The medium- to high-throughput requirement reinforces that NIH is looking for scalable solutions: platforms that can be run repeatedly, standardized, and potentially automated so they can be used broadly for screening and prioritization, not only for one-off mechanistic studies.

Eligibility is restricted to small business concerns, consistent with the SBIR mechanism, and the funding instrument is an R44, which generally corresponds to the SBIR Phase II award level (often used for later-stage development, validation, and preparation for commercialization or broader adoption). Non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, the FOA notes that "foreign components" as defined by the NIH Grants Policy Statement may be allowable, which typically means limited elements of the work could be performed outside the U.S. if they meet NIH requirements and are well-justified, even though the applicant organization itself must be an eligible U.S. small business.

The opportunity is listed under NIH with the funding opportunity number RFA-ES-17-007 and is categorized under environment and health (CFDA 93.113). The original closing date provided is October 4, 2017, and the FOA creation date is June 23, 2017. While the summary here captures what NIH was seeking through that announcement, anyone considering a similar submission would typically need to confirm whether the FOA is still active, whether there are reissues or successor announcements, and what the current NIH requirements are for SBIR eligibility, application structure, and budget rules.

• The National Institutes of Health in the environment, health sector is offering a public funding opportunity titled "Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR R44)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113.
• This funding opportunity was created on 2017-06-23.
• Applicants must submit their applications by 2017-10-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA ES 17 007

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: